Rising Biosciences, Inc. To Offer Cannophen to Patients in Ohio, Florida; Launches Initiatives for National Distribution of Scar Peptide Serum

Sandusky, OH -- February 20, 2018 -- InvestorsHub NewsWire -- Rising India, Inc.'s (OTC: RSII) --Rising Biosciences, Inc., a research and development company focusing on oral and topical pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry, is pleased to announce that it will partner with PAO Group's (OTC: PAOG) Alternative Medicine Centers of America to offer a free trial of Cannophen to patients in the state of Ohio. Anyone with a valid Ohio recommendation can apply for the trial at our Ohio clinics; this will be done on a patient to patient basis.

Cannophen is an oral capsule with laboratory controlled metered dosing that can be blended in exacting ratios of THC, CBD and strain specific terpenes. It is easily digestible and fast acting and designed for patients that do not want to smoke/vape or use off-tasting tinctures.

"This is a monumental event for our company and one that means quite a bit to me personally," states COO Arthur Hall. " I have been using Cannophen since its earliest development stages in hopes to explore and discover its beneficial properties. Initially I was taking for symptoms of Parkinson's and was astounded by overall results: I had also been battling cancer for some time and through surgery, limited chemotherapy and the use of Cannophen I am now cancer free. My physicians are okay with the continued use of Cannophenfor maintenance. We are grateful to be sharing this with other patients beginning with the program in Ohio I also will be meeting with a Producer/Processor in California next week that has demonstrated serious interest in licensing and distributing Cannophen and other Rising Biosciences products".

Mounting evidence shows 'cannabinoids' in marijuana slow cancer growth, inhibit formation of new blood cells that feed a tumor, and help manage pain, fatigue, nausea, and other side effects. According to The National Cancer Institute, Studies in mice and rats have shown that cannabinoids may inhibit tumor growth by causing cell death, blocking cell growth, and blocking the development of blood vessels needed by tumors to grow.

Laboratory and animal studies have shown that cannabinoids may be able to kill cancer cells while protecting normal cells. One notable study of delta-9-THC in hepatocellular carcinoma (liver cancer) cells showed that it damaged or killed the cancer cells. The same study of delta-9-THC in mouse models of liver cancer showed that it had antitumor effects. Delta-9-THC has been shown to cause these effects by acting on molecules that may also be found in non-small cell lung cancer cells and breast cancer cells.

As well, Rising Biosciences is nearing completion on its FDA testing of the TSW (This Sh** Works) pain cream products and is currently working with a company for national distribution of its Scar Peptide Serum.

Rising Biosciences Scar Peptide Serum

The following image depicts a patient who used the serum post-surgery to diminish scars, to astounding results:

Before and after surgery using Rising Bioscience's Scar Peptide Serum to diminish scars

"Rising Biosciences Inc. along with PAO Group Inc. helping reduce the grip of opioids on America through the responsible use of cannabis"

$RSII on Twitter for LIVE company updates!

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

CONTACT INFO: For Investor

Recent Posts